Search
Search
AVS: 2019
Sophie Bakri, MD
Show Description +
Sophie Bakri, MD, reviews her talk from Duke AVS 2019 on intervention in diabetic retinopathy (DR). Dr. Bakri discusses the results of both the PANORAMA and the RISE/RIDE studies to illustrate the need for careful patient selection when treating nonproliferative DR. She says that while it has been shown that anti-VEGF treatment can slow the progression of DR, the potential for loss to follow-up—and the negative effects of anti-VEGF therapy cessation—must be thoughtfully considered when deciding whether or not to initiate treatment in patients with nonproliferative DR.
Posted: 4/26/2019
Sophie Bakri, MD
Sophie Bakri, MD, reviews her talk from Duke AVS 2019 on intervention in diabetic retinopathy (DR). Dr. Bakri discusses the results of both the PANORAMA and the RISE/RIDE studies to illustrate the need for careful patient selection when treating nonproliferative DR. She says that while it has been shown that anti-VEGF treatment can slow the progression of DR, the potential for loss to follow-up—and the negative effects of anti-VEGF therapy cessation—must be thoughtfully considered when deciding whether or not to initiate treatment in patients with nonproliferative DR.
Posted: 4/26/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AVS: 2019.
Please log in to leave a comment.